Last reviewed · How we verify

sulfadoxine pyrimethamine plus piperaquine

London School of Hygiene and Tropical Medicine · Phase 3 active Small molecule

sulfadoxine pyrimethamine plus piperaquine is a Antifolate antimalarial combination with quinoline antimalarial Small molecule drug developed by London School of Hygiene and Tropical Medicine. It is currently in Phase 3 development for Malaria treatment and prevention (Plasmodium falciparum and Plasmodium vivax). Also known as: sulfadoxine pyrimethamine, piperaquine phosphate.

This combination drug inhibits parasite folate synthesis (sulfadoxine-pyrimethamine) and disrupts parasite mitochondrial function (piperaquine) to treat malaria.

This combination drug inhibits parasite folate synthesis (sulfadoxine-pyrimethamine) and disrupts parasite mitochondrial function (piperaquine) to treat malaria. Used for Malaria treatment and prevention (Plasmodium falciparum and Plasmodium vivax).

At a glance

Generic namesulfadoxine pyrimethamine plus piperaquine
Also known assulfadoxine pyrimethamine, piperaquine phosphate
SponsorLondon School of Hygiene and Tropical Medicine
Drug classAntifolate antimalarial combination with quinoline antimalarial
TargetPlasmodium dihydrofolate reductase, dihydropteroate synthase, and parasite mitochondria
ModalitySmall molecule
Therapeutic areaInfectious Disease
PhasePhase 3

Mechanism of action

Sulfadoxine and pyrimethamine are antifolate agents that inhibit dihydrofolate reductase and dihydropteroate synthase in Plasmodium parasites, blocking nucleotide synthesis essential for parasite survival. Piperaquine is a quinoline-type antimalarial that accumulates in parasite food vacuoles and generates reactive oxygen species, causing mitochondrial dysfunction and parasite death. The combination provides synergistic activity against multiple malaria species.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about sulfadoxine pyrimethamine plus piperaquine

What is sulfadoxine pyrimethamine plus piperaquine?

sulfadoxine pyrimethamine plus piperaquine is a Antifolate antimalarial combination with quinoline antimalarial drug developed by London School of Hygiene and Tropical Medicine, indicated for Malaria treatment and prevention (Plasmodium falciparum and Plasmodium vivax).

How does sulfadoxine pyrimethamine plus piperaquine work?

This combination drug inhibits parasite folate synthesis (sulfadoxine-pyrimethamine) and disrupts parasite mitochondrial function (piperaquine) to treat malaria.

What is sulfadoxine pyrimethamine plus piperaquine used for?

sulfadoxine pyrimethamine plus piperaquine is indicated for Malaria treatment and prevention (Plasmodium falciparum and Plasmodium vivax).

Who makes sulfadoxine pyrimethamine plus piperaquine?

sulfadoxine pyrimethamine plus piperaquine is developed by London School of Hygiene and Tropical Medicine (see full London School of Hygiene and Tropical Medicine pipeline at /company/london-school-of-hygiene-and-tropical-medicine).

Is sulfadoxine pyrimethamine plus piperaquine also known as anything else?

sulfadoxine pyrimethamine plus piperaquine is also known as sulfadoxine pyrimethamine, piperaquine phosphate.

What drug class is sulfadoxine pyrimethamine plus piperaquine in?

sulfadoxine pyrimethamine plus piperaquine belongs to the Antifolate antimalarial combination with quinoline antimalarial class. See all Antifolate antimalarial combination with quinoline antimalarial drugs at /class/antifolate-antimalarial-combination-with-quinoline-antimalarial.

What development phase is sulfadoxine pyrimethamine plus piperaquine in?

sulfadoxine pyrimethamine plus piperaquine is in Phase 3.

What are the side effects of sulfadoxine pyrimethamine plus piperaquine?

Common side effects of sulfadoxine pyrimethamine plus piperaquine include Nausea, Vomiting, Abdominal pain, Headache, Diarrhea, Rash.

What does sulfadoxine pyrimethamine plus piperaquine target?

sulfadoxine pyrimethamine plus piperaquine targets Plasmodium dihydrofolate reductase, dihydropteroate synthase, and parasite mitochondria and is a Antifolate antimalarial combination with quinoline antimalarial.

Related